Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors. / Söderhielm, Pella Cecilia; Balle, Thomas; Bak-Nyhus, Søren; Zhang, Michael; Hansen, Karoline M.; Ahring, Philip K.; Jensen, Anders A.

In: Biochemical Pharmacology, Vol. 158, 08.2018, p. 339-358.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Söderhielm, PC, Balle, T, Bak-Nyhus, S, Zhang, M, Hansen, KM, Ahring, PK & Jensen, AA 2018, 'Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors', Biochemical Pharmacology, vol. 158, pp. 339-358. https://doi.org/10.1016/j.bcp.2018.08.019

APA

Söderhielm, P. C., Balle, T., Bak-Nyhus, S., Zhang, M., Hansen, K. M., Ahring, P. K., & Jensen, A. A. (2018). Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors. Biochemical Pharmacology, 158, 339-358. https://doi.org/10.1016/j.bcp.2018.08.019

Vancouver

Söderhielm PC, Balle T, Bak-Nyhus S, Zhang M, Hansen KM, Ahring PK et al. Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors. Biochemical Pharmacology. 2018 Aug;158:339-358. https://doi.org/10.1016/j.bcp.2018.08.019

Author

Söderhielm, Pella Cecilia ; Balle, Thomas ; Bak-Nyhus, Søren ; Zhang, Michael ; Hansen, Karoline M. ; Ahring, Philip K. ; Jensen, Anders A. / Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors. In: Biochemical Pharmacology. 2018 ; Vol. 158. pp. 339-358.

Bibtex

@article{bc9c8f8eb890481a88002ff23d0df22b,
title = "Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors",
abstract = "The extracellular α (+)/γ 2 (-) interface in the α 1,2,3,5βγ 2 GABA A receptor harbours the allosteric binding site targeted by benzodiazepines and newer generations of subtype-selective modulators. We have probed the molecular determinants for the affinity/potency-based α 1-preference exhibited by the hypnotic zolpidem (Ambien{\textregistered}, Stilnox{\textregistered}) and the efficacy-based α 3-over-α 1 selectivity displayed by the analgesic NS11394. Binding affinities and functional properties of the modulators were characterized at wild-type, concatenated, mutant and chimeric α 1,3β 2γ 2S receptors expressed in tsA201 cells and Xenopus oocytes by [ 3H]flumazenil binding and two-electrode voltage clamp electrophysiology. Substitution of Gly 201 in α 1 with the corresponding Glu in α 3 completely eliminated the α 1-over-α 3 preference exhibited by zolpidem. In contrast, the reverse α 3-E225G mutation did not yield corresponding increases in the binding affinity or modulatory potency of zolpidem at α 3β 2γ 2S, and two additional molecular elements in the extracellular domain of the α-subunit were found also to contribute to its α 1-preference. Interestingly, the α 1-Gly 201/α 3-Glu 225 residue was also a key determinant of the efficacy-based α 3-over-α 1 selectivity exhibited by NS11394, and a pronounced correlation existed between the side-chain bulkiness of this residue and the modulatory efficacy of NS11394 at the receptor. The subtype-selectivity determinants identified for zolpidem and NS11394 were found also to apply in different degrees to the α 1-preferring modulator indiplon and the α 3-over-α 1 selective modulator L-838,417, respectively. In conclusion, the molecular origins of subtype-selectivity exhibited by benzodiazepine-site modulators at the α 1,2,3,5βγ 2 GABA A receptor seem more complex than previously appreciated, and the importance of the α 1-Gly 201/α 3-Glu 225 residue for both potency- and efficacy-based subtype-selective modulation through this site is likely to be rooted in different molecular mechanisms. ",
author = "S{\"o}derhielm, {Pella Cecilia} and Thomas Balle and S{\o}ren Bak-Nyhus and Michael Zhang and Hansen, {Karoline M.} and Ahring, {Philip K.} and Jensen, {Anders A.}",
note = "Copyright {\textcopyright} 2018 Elsevier Inc. All rights reserved.",
year = "2018",
month = aug,
doi = "10.1016/j.bcp.2018.08.019",
language = "English",
volume = "158",
pages = "339--358",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors

AU - Söderhielm, Pella Cecilia

AU - Balle, Thomas

AU - Bak-Nyhus, Søren

AU - Zhang, Michael

AU - Hansen, Karoline M.

AU - Ahring, Philip K.

AU - Jensen, Anders A.

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2018/8

Y1 - 2018/8

N2 - The extracellular α (+)/γ 2 (-) interface in the α 1,2,3,5βγ 2 GABA A receptor harbours the allosteric binding site targeted by benzodiazepines and newer generations of subtype-selective modulators. We have probed the molecular determinants for the affinity/potency-based α 1-preference exhibited by the hypnotic zolpidem (Ambien®, Stilnox®) and the efficacy-based α 3-over-α 1 selectivity displayed by the analgesic NS11394. Binding affinities and functional properties of the modulators were characterized at wild-type, concatenated, mutant and chimeric α 1,3β 2γ 2S receptors expressed in tsA201 cells and Xenopus oocytes by [ 3H]flumazenil binding and two-electrode voltage clamp electrophysiology. Substitution of Gly 201 in α 1 with the corresponding Glu in α 3 completely eliminated the α 1-over-α 3 preference exhibited by zolpidem. In contrast, the reverse α 3-E225G mutation did not yield corresponding increases in the binding affinity or modulatory potency of zolpidem at α 3β 2γ 2S, and two additional molecular elements in the extracellular domain of the α-subunit were found also to contribute to its α 1-preference. Interestingly, the α 1-Gly 201/α 3-Glu 225 residue was also a key determinant of the efficacy-based α 3-over-α 1 selectivity exhibited by NS11394, and a pronounced correlation existed between the side-chain bulkiness of this residue and the modulatory efficacy of NS11394 at the receptor. The subtype-selectivity determinants identified for zolpidem and NS11394 were found also to apply in different degrees to the α 1-preferring modulator indiplon and the α 3-over-α 1 selective modulator L-838,417, respectively. In conclusion, the molecular origins of subtype-selectivity exhibited by benzodiazepine-site modulators at the α 1,2,3,5βγ 2 GABA A receptor seem more complex than previously appreciated, and the importance of the α 1-Gly 201/α 3-Glu 225 residue for both potency- and efficacy-based subtype-selective modulation through this site is likely to be rooted in different molecular mechanisms.

AB - The extracellular α (+)/γ 2 (-) interface in the α 1,2,3,5βγ 2 GABA A receptor harbours the allosteric binding site targeted by benzodiazepines and newer generations of subtype-selective modulators. We have probed the molecular determinants for the affinity/potency-based α 1-preference exhibited by the hypnotic zolpidem (Ambien®, Stilnox®) and the efficacy-based α 3-over-α 1 selectivity displayed by the analgesic NS11394. Binding affinities and functional properties of the modulators were characterized at wild-type, concatenated, mutant and chimeric α 1,3β 2γ 2S receptors expressed in tsA201 cells and Xenopus oocytes by [ 3H]flumazenil binding and two-electrode voltage clamp electrophysiology. Substitution of Gly 201 in α 1 with the corresponding Glu in α 3 completely eliminated the α 1-over-α 3 preference exhibited by zolpidem. In contrast, the reverse α 3-E225G mutation did not yield corresponding increases in the binding affinity or modulatory potency of zolpidem at α 3β 2γ 2S, and two additional molecular elements in the extracellular domain of the α-subunit were found also to contribute to its α 1-preference. Interestingly, the α 1-Gly 201/α 3-Glu 225 residue was also a key determinant of the efficacy-based α 3-over-α 1 selectivity exhibited by NS11394, and a pronounced correlation existed between the side-chain bulkiness of this residue and the modulatory efficacy of NS11394 at the receptor. The subtype-selectivity determinants identified for zolpidem and NS11394 were found also to apply in different degrees to the α 1-preferring modulator indiplon and the α 3-over-α 1 selective modulator L-838,417, respectively. In conclusion, the molecular origins of subtype-selectivity exhibited by benzodiazepine-site modulators at the α 1,2,3,5βγ 2 GABA A receptor seem more complex than previously appreciated, and the importance of the α 1-Gly 201/α 3-Glu 225 residue for both potency- and efficacy-based subtype-selective modulation through this site is likely to be rooted in different molecular mechanisms.

U2 - 10.1016/j.bcp.2018.08.019

DO - 10.1016/j.bcp.2018.08.019

M3 - Journal article

C2 - 30121248

VL - 158

SP - 339

EP - 358

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -

ID: 200877351